Nadeer Group Competitors

Al Futtaim Group LLC

WHO WE ARE Emaar is a pioneer of master-planned communities in Dubai since its inception in 1997. It is listed on the Dubai Financial Market as a public joint-stock company. Building upon the legacy of our flagship Downtown Dubai creations — the iconic Burj Khalifa, Dubai Mall, and Dubai Fountain — our dream is to be the world’s most valuable and trusted company, to enrich lives and to be powered by the best people. With proven competencies in properties, shopping malls & retail and hospitality & leisure, we shape new lifestyles with a passion for design excellence, build with quality and timely delivery. EXPANSION & DIVERSIFICATION Reflecting the pulse of Dubai, our portfolio encompasses developing renowned hospitality & leisure projects, premium shopping malls & Retail assets, as well as Master-Planned Communities and iconic Real-Estate assets. Our hospitality & leisure portfolio includes Address Hotels & Resorts and Armani Hotels & Resorts, among others. We are also the developers of premium shopping malls and retail assets such as the flagship The Dubai Mall – the world’s most visited retail & entertainment venue, Dubai Marina Mall and Souk-al-Bahar. Further, we continuously define the standard for exceptional cultural, entertainment and leisure experiences with destinations such as Dubai Opera, Dubai Aquarium & Underwater Zoo, Reel Cinemas, Dubai Ice Rink and VR Park.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.